Beta-blockers are routinely used in all forms of ischaemic heart disease except variant angina. Recently, III generation beta-blockers were introduced into practice. New beta-blockers often have ancillary properties like vaso-dilating or antioxidant properties. Also slow-release formulas of old beta-blockers are now available. Several studies show that these new agents are more efficient when compared with old beta-blockers. Moreover, adverse effects of new beta-blockers are often less severe than in the case of older agents. Especially the influence on bronchi, peripheral arteries and lipid and glucose metabolism is less pronounced. The frequency of beta-blockers use is too low in Poland as well as in other European countries, despite overwhelming evidence that these agents improve prognosis. The results of Cracovian Program for Secondary Prevention of Ischaemic Heart Disease showed that the proportions of patients after myocardial infarction or myocardial revascularization prescribed beta-blockers are too low. One of the reasons is probably the doctors' concern about side effects of beta-blockers. Widespread use of new beta-blockers in everyday clinical practice may increase beta-blocker use in general and in this way improve prognosis of ischaemic heart disease patients in Europe.